Effects of sodium-glucose cotransporter 2 inhibitors on urinary excretion of intact and total angiotensinogen in patients with type 2 diabetes.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: SAGE Publications Country of Publication: England NLM ID: 9501229 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1708-8267 (Electronic) Linking ISSN: 10815589 NLM ISO Abbreviation: J Investig Med Subsets: MEDLINE
    • Publication Information:
      Publication: 2023-: [Thousand Oaks] : SAGE Publications
      Original Publication: Thorofare, NJ : Slack, c1994-
    • Subject Terms:
      Sodium-Glucose Transporter 2 Inhibitors*; Angiotensinogen/*urine ; Diabetes Mellitus, Type 2/*urine; Adult ; Aged ; Aged, 80 and over ; Albuminuria/urine ; Blood Glucose ; Blood Pressure ; Creatinine/urine ; Diabetes Mellitus, Type 2/physiopathology ; Diastole ; Female ; Humans ; Male ; Middle Aged ; Sodium-Glucose Transporter 2/metabolism ; Systole
    • Abstract:
      We conducted a descriptive case study to examine the effects of sodium-glucose cotransporter 2 (SGLT2) inhibitors on urinary angiotensinogen excretion, which represents the function of the intrarenal renin-angiotensin system, in patients with type 2 diabetes. An SGLT2 inhibitor (canagliflozin 100 mg/day, ipragliflozin 25 mg/day, dapagliflozin 5 mg/day, luseogliflozin 2.5 mg/day or tofogliflozin 20 mg/day) was administered for 1 month (n=9). ELISA kits were used to measure both urinary intact and total angiotensinogen levels. Treatment with SGLT2 inhibitors significantly decreased hemoglobin A1c, body weight, systolic blood pressure and diastolic blood pressure (8.5±1.3 to 7.5%±1.0%, 82.5±20.2 to 80.6±20.9 kg, 143±8 to 128±14 mm Hg, 78±10 to 67±9 mm Hg, p<0.05, respectively), while urinary albumin/creatinine ratio was not significantly changed (58.6±58.9 to 29.2±60.7 mg/g, p=0.16). Both total urinary angiotensinogen/creatinine ratio and intact urinary angiotensinogen/creatinine ratio tended to decrease after administration of SGLT2 inhibitors. However, these changes were not significant (p=0.19 and p=0.08, respectively). These data suggest that treatment with SGLT2 inhibitors does not activate the intrarenal renin-angiotensin system in patients with type 2 diabetes.
      Competing Interests: Competing interests: None declared.
      (© American Federation for Medical Research (unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.)
    • Comments:
      Comment in: J Investig Med. 2018 Feb;66(2):e4. (PMID: 29030417)
    • References:
      Clin Ther. 2016 Jan 1;38(1):66-88.e20. (PMID: 26718606)
      Cardiovasc Diabetol. 2014 Mar 28;13:65. (PMID: 24678906)
      Hosp Pract (1995). 2013 Apr;41(2):72-84. (PMID: 23680739)
      Am J Med Sci. 2009 Dec;338(6):478-80. (PMID: 19884815)
      J Clin Invest. 1994 Jan;93(1):397-404. (PMID: 8282810)
      Clin Drug Investig. 2016 Apr;36(4):313-9. (PMID: 26914659)
      Am J Physiol Renal Physiol. 2007 Sep;293(3):F956-60. (PMID: 17553939)
      Circulation. 2014 Feb 4;129(5):587-97. (PMID: 24334175)
      Clin Sci (Lond). 2005 Aug;109(2):143-59. (PMID: 16033329)
      Diabetes Care. 2004 Oct;27(10):2568-9; author reply 2569. (PMID: 15451946)
      Lancet Diabetes Endocrinol. 2014 May;2(5):369-84. (PMID: 24795251)
      Diabetes Care. 1998 Sep;21(9):1414-31. (PMID: 9727886)
      J Pharmacol Sci. 2012;119(4):314-23. (PMID: 22850612)
      Diabetes Metab Syndr Obes. 2012;5:313-27. (PMID: 22977310)
      Diabetologia. 2016 Sep;59(9):1860-70. (PMID: 27316632)
      Ann Surg Oncol. 2016 Aug;23(Suppl 4):467-474. (PMID: 27364511)
      Pharmacol Rev. 2007 Sep;59(3):251-87. (PMID: 17878513)
      Can J Physiol Pharmacol. 2014 Aug;92(8):703-6. (PMID: 24920267)
      J Biol Chem. 1994 May 27;269(21):15204-9. (PMID: 8195156)
      N Engl J Med. 2016 Jul 28;375(4):323-34. (PMID: 27299675)
      Curr Opin Nephrol Hypertens. 2010 Sep;19(5):425-31. (PMID: 20539226)
      Kidney Int. 2014 Apr;85(4):962-71. (PMID: 24067431)
      Hypertension. 2011 Aug;58(2):205-11. (PMID: 21670416)
      N Engl J Med. 2015 Nov 26;373(22):2117-28. (PMID: 26378978)
      Can J Diabetes. 2014 Oct;38(5):356-63. (PMID: 25192954)
      Diabetes Care. 2016 Jan;39 Suppl 1:S4-5. (PMID: 26696680)
      J Diabetes Complications. 2013 May-Jun;27(3):268-73. (PMID: 23276620)
      Lancet. 2010 Jun 26;375(9733):2223-33. (PMID: 20609968)
      Kidney Int. 2014 Nov;86(5):1057-8. (PMID: 25360497)
      Diabetes Metab Syndr Obes. 2013 Nov 27;6:453-67. (PMID: 24348059)
      Diabetes Obes Metab. 2016 Jun;18(6):590-7. (PMID: 26936519)
      Adv Ther. 2015 Nov;32(11):1085-103. (PMID: 26530268)
      Am J Physiol Renal Physiol. 2016 Dec 1;311(6):F1211-F1216. (PMID: 27511456)
      Diabetes Care. 2015 Mar;38(3):384-93. (PMID: 25583754)
    • Grant Information:
      R01 DK072408 United States DK NIDDK NIH HHS
    • Contributed Indexing:
      Keywords: SGLT2 inhibitor; blood pressure; type 2 diabetes; urinary albumin; urinary angiotensinogen
    • Accession Number:
      0 (Blood Glucose)
      0 (SLC5A2 protein, human)
      0 (Sodium-Glucose Transporter 2)
      0 (Sodium-Glucose Transporter 2 Inhibitors)
      11002-13-4 (Angiotensinogen)
      AYI8EX34EU (Creatinine)
    • Publication Date:
      Date Created: 20170610 Date Completed: 20180528 Latest Revision: 20181202
    • Publication Date:
      20240628
    • Accession Number:
      PMC5812257
    • Accession Number:
      10.1136/jim-2017-000445
    • Accession Number:
      28596160